Biotech Values

[ronpopeil]

Enanta Pharmaceuticals beats by $0.11, beats on revenues • 7:41 AM

Enanta Pharmaceuticals (ENTA): FQ3 EPS of -$0.23 beats by $0.11.
Revenue of $1.65M beats by $0.92M. (PR)

Cash, cash equivalents and marketable securities totaled $114.8 million at June 30, 2013. This compares to $45.4 million at September 30, 2012.

Recent Developments

Six Phase 3 registration studies that include ABT-450, Enanta and AbbVie’s collaborative protease inhibitor for hepatitis C (HCV), are fully enrolled, and a New Drug Application is expected to be filed in calendar 2Q 2014
Combination studies of ABT-493 (Enanta and AbbVie’s next-generation collaborative protease inhibitor for HCV) with ABT-530 (AbbVie’s next-generation NS5A inhibitor) were recently initiated, and Phase 2 studies are expected to begin in 2013
Enanta was added to the Russell 3000 and Russell 2000 Indexes on June 28, 2013
A proof-of-concept study of EDP-239 (Enanta’s NS5A inhibitor) was recently initiated by Novartis, Enanta’s development partner for NS5A compounds for HCV

Upcoming Events and Presentations

Enanta management will participate at the following events:

August 12, 2013: Jefferies 2013 Boston Healthcare Summit, Boston, MA
September 3, 2013: Citi’s 8th Annual Biotech Conference, Boston, MA
September 11-12, 2013: Stifel 2013 Healthcare Conference, Boston, MA